DEF: Werewolf Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Seeks Director Elections and Auditor Ratification

Werewolf Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on June 12, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

Summary

• Werewolf Therapeutics will hold its 2025 annual meeting of stockholders virtually on June 12, 2025, at 9:00 a.m. Eastern time.
• Stockholders of record as of April 14, 2025, are eligible to vote.
• The meeting will address the election of three Class I directors for three-year terms expiring in 2028.
• The meeting will also address the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board recommends voting FOR the election of the director nominees and FOR the ratification of Ernst & Young LLP.
• The company is using the notice and access approach for proxy materials, mailing a Notice of Internet Availability of Proxy Materials on or about April 28, 2025.
• Derek DiRocco, Ph.D., a Class II director, will resign effective upon the Annual Meeting, reducing the board size to eight members.

Sentiment

Score: 7

Explanation: The document is primarily procedural and informational, with a neutral to slightly positive tone due to the board's recommendations and the company's efforts to enhance stockholder participation.

Positives

• The company is embracing a virtual meeting format to enable greater stockholder attendance and participation from any location around the world.
• The board of directors is recommending qualified candidates for election as Class I directors.
• The board of directors is recommending the ratification of a well-established independent registered public accounting firm.

Negatives

• Derek DiRocco, Ph.D., will resign effective upon the Annual Meeting, reducing the board size to eight members.

Risks

• Failure to achieve a quorum could lead to adjournment of the Annual Meeting.
• If stockholders do not ratify the appointment of Ernst & Young LLP, the audit committee will reconsider the appointment, potentially leading to increased costs and disruption.
• The loss of Derek DiRocco, Ph.D., from the board of directors could impact the board's expertise and decision-making capabilities.

Future Outlook

The board of directors intends to continue to review and refine its corporate governance practices to ensure they align with the company's strategic goals and stockholder interests.

Management Comments

• Daniel J. Hicklin, President and Chief Executive Officer, encourages stockholders to vote their shares to ensure representation and the presence of a quorum at the Annual Meeting.

Industry Context

The use of a virtual annual meeting format reflects a growing trend in corporate governance to enhance accessibility and participation for stockholders, particularly in geographically diverse companies.

Comparison to Industry Standards

• The director compensation program is designed to attract and retain highly qualified non-employee directors, which is a common practice among publicly traded companies.
• The company's clawback policy is compliant with Nasdaq listing standards, aligning with industry best practices for executive compensation governance.
• The company's insider trading policy and anti-hedging and pledging policy are consistent with industry standards to prevent insider trading and promote compliance with securities laws.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a royalty transfer agreement with MPM Oncology Impact Fund Charitable Foundation, Inc., and UBS Optimus Foundation, requiring royalty payments of 0.5% of net sales of certain products to each foundation.
• The company entered into indemnification agreements with all of its directors and executive officers.
• In May 2022, the company entered into a sublease agreement with Crossbow, to sublease to Crossbow the entirety of our office and laboratory space in Cambridge, Massachusetts. The term of the sublease agreement commenced in June 2022 and ended in March 2024.

Stakeholder Impact

• Stockholders are encouraged to participate in the Annual Meeting and vote on the proposals.
• The election of directors and ratification of the auditor will impact the company's governance and financial oversight.
• The company's compensation policies and related party transactions are subject to review and approval by the board of directors and its committees.

Next Steps

• Stockholders should review the proxy materials and vote their shares by the specified deadlines.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Ernst & Young, Stockholders, Corporate Governance, Voting, Werewolf Therapeutics